Ractigen Therapeutics Completes Phase II Enrollment for SOD1-ALS siRNA RAG-17; LiCO Therapy RAG-18 for DMD Receives Rare Pediatric Disease Designation

August 17, 2026

Facebook China

Overview

Ractigen Therapeutics announced the completion of patient enrollment and first dosing in its Phase II clinical trial for RAG-17, an investigational siRNA therapy for SOD1-mutated amyotrophic lateral sclerosis (ALS). Concurrently, its subcutaneous lipid-conjugated oligonucleotide (LiCO) therapy, RAG-18, for Duchenne muscular dystrophy (DMD) received Rare Pediatric Disease Designation from the U.S. FDA. These advancements highlight Ractigen’s accelerated development of RNA-based therapies for debilitating neuromuscular diseases, offering new hope to patients.

In Depth

Key Findings

Ractigen Therapeutics has announced the successful completion of patient enrollment and initial dosing in its Phase II clinical trial for RAG-17, an investigational siRNA therapy aimed at treating SOD1-mutated amyotrophic lateral sclerosis (ALS). In parallel, the company’s subcutaneous lipid-conjugated oligonucleotide (LiCO) therapy, RAG-18, for Duchenne muscular dystrophy (DMD), has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). These milestones underscore Ractigen’s accelerated efforts in developing RNA-based therapeutics for high-unmet-need neuromuscular diseases.

Technical / Clinical Details

RAG-17 is an siRNA designed to suppress the production of abnormal SOD1 protein, which is caused by mutations in the SOD1 gene. SOD1 mutations account for approximately 20% of ALS cases and are believed to be directly involved in disease progression. As siRNA silences gene expression by degrading target mRNA, it holds the potential to intervene in the root cause of the disease. The completion of Phase II enrollment indicates that further data on the drug’s safety and preliminary efficacy are anticipated. RAG-18 is a novel LiCO therapy for DMD, offering the advantage of subcutaneous administration compared to existing antisense oligonucleotide (ASO) therapies. The Rare Pediatric Disease Designation provides FDA incentives to foster the development of therapies for rare pediatric diseases, potentially including expedited review and eligibility for a priority review voucher.

Background & Context

Amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD) are both progressive neuromuscular disorders with no current curative treatments and extremely high unmet medical needs. RNA-based therapeutics, particularly siRNAs and ASOs, are drawing attention as promising therapeutic modalities due to their ability to address the genetic causes of these intractable diseases at the molecular level. The development of specialized RNA therapies for these conditions by biotech companies like Ractigen offers significant hope to patients and their families. The potential for subcutaneous administration offered by LiCO technology is particularly important for enhancing patient convenience and reducing the burden of treatment.

Strategic Significance & Outlook

The Phase II results for RAG-17 will be crucial in clarifying the efficacy and safety profile of siRNA therapy in SOD1-ALS treatment. Furthermore, the Rare Pediatric Disease Designation for RAG-18 is expected to accelerate patient access for DMD and boost its clinical development. These advancements from Ractigen Therapeutics suggest that RNA-based technologies could revolutionize the treatment of neuromuscular diseases that have been difficult to address. Should these programs succeed in clinical trials, they will not only provide new treatment options to patients but also stimulate further development of RNA therapies for other neurodegenerative and genetic disorders. Ractigen’s innovations are anticipated to play a significant role in shaping the future of treating rare and challenging diseases.

Source: https://www.facebook.com/groups/2688029951255361/posts/28182544668043872/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.